Date:
April 2, 2003 at 7:00pm
Cost: $20 at the door.
Location: Wilson
Sonsini Goodrich and Rosati
950 Page Mill Road, Palo
Alto
Click for Directions
Rodney Ferguson Slides
Matthew Plunkett Slides
So you've noticed that tools, technologies, genomics and bioinformatics are
no longer fundable business models. And that most of the companies getting
financed in the last year were biopharmaceutical companies with products
already in the clinic. Why are biopharma products now in favor with the
venture community? why are the business models of the late 90s no longer in
vogue?
We'll hear from a Wall Street-savvy banker and a Genentech alum turned
venture capitalist. Please join us on April 2 when Matthew Plunkett (CIBC
Capital Markets) and Rodney Ferguson (JP Morgan Chase Capital) give us their
views on what business models are fundable.
Networking session will follow.
Click Here to RSVP for this Event
Presenters:
|
Rodney Ferguson, J.D., Ph.D., Managing Director, JPMorgan Partners
|
|
Dr. Rodney Ferguson is a Managing Director in the San Francisco office of
JPMorgan Partners and co-head of the Life Sciences and Healthcare
Infrastructure team responsible for all healthcare investments by JPMorgan
Partners worldwide. Prior to joining JPMorgan Partners, Dr. Ferguson was a
General Partner at InterWest Partners focusing on investments in medical
technology, including biopharmaceuticals, genomics, medical devices, and
bioware applications. Prior to joining InterWest in 1999, Dr. Ferguson was
Senior Director of Business and Corporate Development at Genentech, Inc., a
leading biotechnology company, where he was responsible for worldwide
licensing activities including both in-licensing of early-stage and
development-stage pharmaceutical products as well as out-licensing of
Genentech development projects. In addition, Dr. Ferguson played a key role
in strategic planning activities for Genentech outside its core therapeutic
focus in oncology and cardiovascular medicines. Prior to joining the
business and corporate development department at Genentech in 1993, Dr.
Ferguson was Senior Corporate Counsel in Genentech's legal department. Prior
to joining Genentech in 1988, Dr. Ferguson was an associate at McCutchen,
Doyle, Brown & Enersen in San Francisco. Dr. Ferguson earned his
undergraduate degree in Biochemistry from the University of Illinois in 1977,
his Ph.D. in Biochemistry from the State University of New York at Buffalo in
1981 and his J.D. from Northwestern University in 1984.
|
|
Matthew Plunkett, Ph.D., Director, CIBC World Markets Healthcare Investment
Banking
|
|
Dr. Plunkett joined CIBC World Markets in December 2000. His experience
includes a variety of completed transactions, including IPOs, follow-on
offerings, convertible debt, private placements, and M&A assignments. He
works frequently with smaller and early-stage companies on addressing their
financial and strategic goals. Previously he worked at Sunesis
Pharmaceuticals where he lead a team of 6 focused on the company's
"monophore" technology, and at Axys Advanced Technologies working on various
drug discovery projects. He received a BS (Honors) in Chemistry, with a
History concentration, from Harvey Mudd College, and a Ph.D in Organic
Chemistry from the University of California, Berkeley.
|
|
